Enliven Therapeutics (Nasdaq: ELVN) grants inducement for small molecule therapeutics development.
Boulder, Colorado, Dec. 11, 2025 - Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company traded on Nasdaq under the symbol ELVN, revealed today that they have awarded a significant grant on the same date. Enliven is dedicated to identifying and advancing small molecule therapeutics.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments